Evidence map›Paper›PMID 42313104›Full record

ArticleAntimicrobial agents and chemotherapy2026

Discovery and characterization of a hydroxypyridone-3-carboxamide analog as an antiviral lead against orthopoxviruses.

Anil Pant, Ajit Jagtap, Jiashu Xie, Djamal Brahim Belhaouari, Wei Xie, Jacob P Mahoney, Lara Dsouza, Ziyue Wang, Zeinab R Aboezz, Tibor Farkas and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Anil PantDepartment of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.ORCID 0000-0003-4914-1771
Ajit JagtapCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-0101-6392
Jiashu XieCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
Djamal Brahim BelhaouariDepartment of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
Wei XieCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
Jacob P MahoneyCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-7174-9161
Lara DsouzaDepartment of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
Ziyue WangDepartment of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
Zeinab R AboezzDepartment of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
Tibor FarkasDepartment of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.ORCID 0009-0004-4246-1275
Zhengqiang WangCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-1326-5986
Zhilong YangDepartment of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.ORCID 0000-0001-8995-2654

Funding

Development of novel antivirals against mpox (monkeypox) virusR01AI183580 · NIAID · UNIVERSITY OF MINNESOTA · PI Zhengqiang Wang, Zhilong Yang · 2024 to 2026
$2.3M
NIAID NIH HHS R01 AI183580NIH HHS R01AI139137NIH HHS R01AI183580
6 · The paper itself

Abstract

Orthopoxviruses remain a persistent global health concern due to the ongoing circulation of mpox, the possibility of the re-emergence of smallpox, and the threats posed by many poxviruses that infect animals and/or humans. The limited availability of antiviral drugs, the unproven efficacy in humans, and the emergence of resistant mutants underscore the need for new and better therapeutics. In this study, we identify and characterize ZW-2038, a hydroxypyridone-3-carboxamide analog, as an antiviral compound against vaccinia virus (VACV), monkeypox virus (MPXV), and cowpox virus (CPXV). Discovered through a focused in-house small-molecule screen, ZW-2038 exhibited low micromolar potency and high selectivity in primary human fibroblasts. The compound also reduced viral replication under physiomimetic conditions, including human and monkey intestinal organoids (enteroids) and

Indexed as

Antiviral AgentsOrthopoxvirusPyridonesAnimalsChlorocebus aethiopsCowpox virusFibroblastsHumansMiceMonkeypox virusVaccinia virusVirus ReplicationAntiviral AgentsPyridonesantiviralenteroidsex vivo lung tissuehydroxypyridone-3-carboxamideMpoxorganoidsorthopoxvirus

Identifiers

PMID42313104
PMCPMC13286052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.